Drug utilization study and safety evaluation based on prediction approach for drug interactions in chemotherapy

Research Project

Project/Area Number	22790511
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Single-year Grants
Research Field	Applied pharmacology
Research Institution	Kanazawa University
Principal Investigator	YOSHIDA Naoko 金沢大学, 薬学系, 助教 (20565428)
Project Period (FY)	2010 – 2011
Project Status	Completed (Fiscal Year 2011)
Budget Amount *help	¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000) Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Keywords	医薬品副作用・相互作用 / がん化学療法 / 漢方薬 / 安全性
Research Abstract	The aim of this study was to describe utilization of anticancer drugs and concomitant medicines including Kanpo medicines, and evaluate safety of concomitant Kampo medicines in chemotherapy. As a result, Co-administration of Daikenchuto or Hangeshashinto, in patients treated with paclitaxel or irinotecan, respectively, showed significant association with decrease of platelet count over grade 3 based on Common Terminology Criteria for Adverse Events v4. 0 criteria. In addition, some of co-administrated Kampo medicines could affect occurrence of adverse effects, such as myelosuppression, electrolyte abnormality, or hepatic dysfunction.